Ultime notizie per Adlai Nortye (NASDAQ:ANL) Azioni

Adlai Nortye

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Adlai Nortye Ltd. - American Depositary Shares

Adlai Nortye Ltd

Aton Resources Inc

ANFIELD ENERGY INC by Anfield Energy Inc.

Anfield Energy Inc

News

Contracts

KOPN

Kopin Announces That Startup Get Your Way Selected Co.'s Golden Pearl Optical Module For Its aRdent 2 Assisted Reality Solution

Says Medical Insurance Probe Is "Historic", In Past, Not Involving Any Current Executives; Medical Insurance Probe Began Three Years Ago, Initially Involved Small Number Of Employees; Now 100 Former Employees Have Been Sentenced To Jail Time
-Investor Call

AstraZeneca Says Arrests Of Current And Former Staff Mentioned By CEO In September To Bloomberg Are A Third Issue, Unrelated To Medical Insurance And Wang Investigations; Sought To Quell Concerns About China Business After Report Of Broader Probe Into Potential Insurance Fraud; China Exec. Leon Wang Is Detained By Chinese Authorities As Part Of The Investigation; To The Company's Knowledge; Medical Insurance Probe Reported By Yicai Is Separate From The Leon Wang Investigation

Guidance

Pinnacle West Capital  Estimates 2025 EPS Of $4.40 - $4.60 On Weather-normalized Basis, Est $4.78

IGC Pharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGC#NYSE">IGC</a>) ("IGC Pharma" or the "Company") is pleased to announce the publication of a new interview with CEO Ram Mukunda, now available as part of the IMS Spotlight Series.
In the interview, Ram Mukunda discusses IGC's strategic expansion into metabolic and neurological markets, specifically addressing the potential of GLP-1 agonists in both Alzheimer's and weight loss therapies. Mukunda also provides updates on IGC Pharma's lead candidate, IGC-AD1, which is currently in Phase 2 trials for treating agitation in Alzheimer's dementia and is progressing toward additional trials to explore its potential as a disease-modifying treatment.
The interview underscores IGC's approach to leveraging artificial intelligence to diversify its pipeline, targeting both neurodegenerative and metabolic disorders to maximize patient impact.
To read the full interview, please visit: <a href="https://pr.report/41tx">Expanding Our Portfolio: IGC Pharma's Strategic Growth in Alzheimer's and Weight Loss Therapies</a>

Biotech

General

IGC Pharma Announces Publication Of IMS Spotlight Interview With CEO Ram Mukunda Highlighting Strategic Expansion In Alzheimer's And Weight Loss Therapies

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">Royalty Pharma plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>)</h3>
<ul>
<li>Dividend Yield: 3.05%</li>
<li>Citigroup analyst Andrew Baum maintained a Buy rating and cut the price target from $60 to $40 on Oct. 25. This analyst has an accuracy rate of 72%.</li>
<li>Morgan Stanley analyst Terence Flynn maintained an Overweight rating and raised the price target from $48 to $51 on July 11. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: On Nov. 4, Royalty Pharma and Syndax Pharmaceuticals entered into $350 million royalty funding agreement for Niktimvo.</li>
<li>Benzinga Pro's real-time newsfeed alerted to l<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">atest RPRX news. </a></li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/21cac52e-a5a5-4623-954e-111f57f53a6d" alt="" style="width:638px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</h3>
<ul>
<li>Dividend Yield: 3.13%</li>
<li>Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $180 to $185 on Oct. 16. This analyst has an accuracy rate of 77%.</li>
<li>Wells Fargo analyst Larry Biegelsen maintained an Equal-Weight rating and increased the price target from $163 to $166 on Oct. 16. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Oct. 28, Johnson &amp; Johnson announced results from the Phase 3 GRAVITI study of Tremfya (guselkumab) for Crohn's disease.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"> latest JNJ news.</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/572ca32b-5a3e-4fc3-b873-df0527702e1f" alt="" style="width:659px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Medtronic plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>)</h3>
<ul>
<li>Dividend Yield: 3.12%</li>
<li>Truist Securities analyst Richard Newitter maintained a Hold rating and raised the price target from $90 to $93 on Oct. 14. This analyst has an accuracy rate of 74%.</li>
<li>Citigroup analyst Joanne Wuensch maintained a Neutral rating and increased the price target from $85 to $92 on Oct. 1. This analyst has an accuracy rate of 77%.</li>
<li>Recent News: Medtronic will report financial results for its second quarter of fiscal year 2025 on Tuesday, Nov. 19.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">trend in MDT stoc</a>k. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="841" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png" alt="" class="wp-image-632327" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06043120/image-48-768x713.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a>

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

RPRX

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 3% Dividend Yields

WIIM

Broadridge Financial Solutions shares are trading higher after Morgan Stanley raised its price target on the stock from $200 to $207.

Keybanc analyst Eric Gonzalez maintains Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) with a Overweight and lowers the price target from $80 to $78.

Keybanc Maintains Overweight on Restaurant Brands Intl, Lowers Price Target to $78

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d94a96b85e930001fd9dd4/kevin-dede">HC Wainwright &amp; Co. analyst Kevin Dede</a> initiated coverage on BitFuFu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) with a Buy rating and announced a price target of $7. BitFuFu shares closed at $4.57 on Tuesday. <a href="https://www.benzinga.com/quote/FUFU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst David Katz initiated coverage on Ryman Hospitality Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) with a Buy rating and announced a price target of $130. Ryman Hospitality shares closed at $108.30 on Tuesday. <a href="https://www.benzinga.com/quote/RHP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61826cd080db050001bbb18a/jiong-shao">Barclays analyst Jiong Shao</a> initiated coverage on Vipshop Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) with an Overweight rating and announced a price target of $19. Vipshop shares closed at $14.58 on Tuesday. <a href="https://www.benzinga.com/quote/VIPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Gary Mobley initiated coverage on Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) with an Overweight rating and announced a price target of $62. Rambus shares closed at $50.26 on Tuesday. <a href="https://www.benzinga.com/quote/RMBS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Lee Hambright initiated coverage on Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with an Outperform rating and announced a price target of $300. Insulet shares closed at $241.32 on Tuesday. <a href="https://www.benzinga.com/quote/PODD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PODD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-1024x582.png" alt="" class="wp-image-632774" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51.png 1178w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Initiation

FUFU

PODD

RMBS

VIPS

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

LQR House Inc. (the "Company" or "LQR House") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LQR#NASDAQ">LQR</a>), a niche e-commerce platform specializing in the spirits and beverage industry,is thrilled to announce a new marketing collaboration with The New York Cocktail Co., including a launch of a custom campaign highlighting their award-winning ready-to-drink cocktail Negroni, crafted by their team of New York's bartenders. This campaign will focus on driving traffic and sales for their bottled Negroni cocktail on <a href="https://pr.report/41m0">CWSpirits.com</a>.
According to The New York Cocktail Co., their Negroni is more than just a cocktail; it offers convenience without compromising quality, capturing the essence of the bartender-guest connection in every pour. It stands as a tribute to Dante NYC-an iconic Greenwich Village café and a landmark in New York's cocktail scene since 1915. Renato Tonelli, an Italian-American Beverage Director at Dante and the 2023 U.S. Bartender of the Year, has brought his expertise to create this spirited, herbaceous, and impeccably balanced Negroni, now bottled for The New York Cocktail Co.

LQR House Announces Marketing Partnership With The New York Cocktail Co. To Drive Awareness And Sales Of Their Negroni Cocktail On CWSpirits.com

Pinnacle West Capital Adjusts 2024 EPS Guidance Upward From $4.60 - $4.80 To  $5.00 - $5.20, Est $4.85

Tencent Music shares are trading lower. Barclays initiated coverage on the stock and announced a price target of $16.

Nvni Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNI#NASDAQ">NVNI</a>) ("Nuvini"), a leading B2B SaaS acquirer in Latin America, is pleased to announce the successful close of its latest financing round, consisting of a combination of equity and convertible notes. The financing, led by Nuvini's Founder and CEO, Pierre Schurmann, and existing investors, underscores the company's strategic growth vision.
The convertible notes were secured at a conversion price of $1.10 per share. The premium pricing signals not only the company's founder and investors' belief in the company's resilience and growth potential but also a shared commitment to building a robust foundation for sustainable, long-term expansion.
In addition to this strategic financing milestone, Nuvini is pleased to announce the promotion of Mr José Mario Ribeiro to the role of Chief Operating Officer. Since the announcement of Jose Mario as Board Advisor in August, he has made significant contributions to the company, and his transition to this expanded role will enable Nuvini to accelerate its focus on embedding finance within its portfolio companies, further amplifying operational efficiencies and growth opportunities.

Management

NVNI

Nuvini Appoints José Mario Ribeiro As New Chief Operating Officer

REBN

Reborn Coffee Announced It Has Closed Its Acquisition Of A 58% Stake In South Korean Bbang Ssaem Bakery; Terms Not Disclosed

Jones Lang LaSalle shares are trading higher after the company reported better-than-expected Q3 financial results.

The Company's innovative alcohol-reducing beverage, Sure Shot, will be available in 450+ stores across the Chicago area.
JUPITER, Fla., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) ("Safety Shot" or "the Company") today announced a new distribution agreement with Huckster, Inc., a leading Direct-to-Store (DSD) distributor in Illinois, to expand the availability of its innovative alcohol-reducing beverage, Sure Shot, in the metro Chicago market.
Sure Shot, the first beverage of its kind, is specifically formulated to reduce blood alcohol content while enhancing mental clarity. Its unique blend of essential B vitamins, antioxidants, electrolytes, and nootropics supports the body's natural metabolic processes to efficiently process alcohol, reducing blood alcohol content (BAC) in as little as 30 minutes. This innovative approach, backed by a recently awarded patent and positive clinical study results, positions Sure Shot as the ideal choice for health-conscious individuals who enjoy an active social life.

SHOT

Safety Shot Expands Reach In Metro Chicago With New Distribution Agreement With Huckster, Inc.

Keybanc analyst Steve Barger downgrades Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) from Overweight to Sector Weight.

Downgrades

Keybanc Downgrades Myers Indus to Sector Weight

EFSH

1847 Holdings Signs Definitive Agreement To Acquire A Cabinet, Door & Millwork Manufacturer For $18.75M

SMCI

Super Micro Computer shares are trading lower after JP Morgan downgraded the stock from Neutral to Underweight and cut its price target on the stock from $50 to $23.

Pinnacle West Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNW#NYSE">PNW</a>) reported quarterly earnings of $3.37 per share which missed the analyst consensus estimate of $3.48 by 3.16 percent. This is a 3.71 percent decrease over earnings of $3.50 per share from the same period last year. The company reported quarterly sales of $1.77 billion which missed the analyst consensus estimate of $1.87 billion by 5.65 percent. This is a 7.94 percent increase over sales of $1.64 billion the same period last year.

Earnings

Earnings Misses

Pinnacle West Capital Q3 2024 GAAP EPS $3.37 Misses $3.48 Estimate, Sales $1.77B Miss $1.87B Estimate

Both novel bifunctional (SON-1411) and monofunctional (SON-1400) fusion proteins exhibit wild-type binding to the IL-18 receptor (IL-18Rc), coupled with undetectable binding to the inhibitory IL-18 binding protein (IL-18BP)
IL-18 has significant importance for cancer immune-oncology and combination with IL-12 on Sonnet's FHAB platform which Sonnet believes could&nbsp;present an important oncology possibility
The lock-and-load flexibility of the FHAB platform offers the bifunctional payload capability of adding another synergistic biologics target to IL-18 generating multiple novel cancer drugs
PRINCETON, NJ, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,134,635 entitled "Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same," covering two of its novel drug candidates, SON-1411 (IL-18BPR-FHAB-IL12) and SON-1400 (IL-18BPR-FHAB), each containing a modified version of recombinant human interleukin-18 (IL-18BPR = Binding Protein Resistant). The patent carries a term effective until June 2044.

SONN

Sonnet BioTherapeutics Announces Issuance Of U.S. Patent Covering A Variant IL-18 Incorporated Into Two Novel Immunotherapeutic Drug Candidates; Both Novel Bifunctional And Monofunctional Fusion Proteins Exhibit Wild-Type Binding To The IL-18 Receptor, Coupled With Undetectable Binding To The Inhibitory IL-18 Binding Protein

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the trading week with a look at the biggest pre-market stock movers for Monday morning!



Moving stocks this morning are earnings, investments, a delisting and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Moolec Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlec-stock-quote/">MLEC</a>) stock is rocketing more than 67% on approval for its <a href="https://www.nasdaq.com/press-release/moolec-becomes-first-molecular-farming-company-to-achieve-usda-approval-for-plant">plant-groan animal proteins</a>.</li>



<li>OLB Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) shares are soaring over 46% with heavy pre-market trading.</li>



<li>Complete Solaria (NASDAQ:<a href="https://investorplace.com/stock-quotes/cslr-stock-quote/">CSLR</a>) stock is surging more than 42% <a href="https://www.nasdaq.com/press-release/retail-stock-sector-and-chairman-t.j.-rodgers-invest-in-complete-solaria-2024-04-21">on investment news</a>.</li>



<li>SuperCom (NASDAQ:<a href="https://investorplace.com/stock-quotes/spcb-stock-quote/">SPCB</a>) shares are gaining over 33% ahead of its <a href="https://www.nasdaq.com/press-release/supercom-to-report-fourth-quarter-and-full-year-2023-financial-results-on-april-22">Q4 2023 earnings report</a> this morning.</li>



<li>Dermata Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/drma-stock-quote/">DRMA</a>) stock is rising more than 18% on Monday morning.</li>



<li>Galera Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/">GRTX</a>) shares are increasing over 17% without any clear news this morning.</li>



<li>Palisade Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pali-stock-quote/">PALI</a>) stock is climbing more than 16% despite a lack of news today.</li>



<li>Global Gas (NASDAQ:<a href="https://investorplace.com/stock-quotes/hgas-stock-quote/">HGAS</a>) shares are heading over 14% higher on Monday.</li>



<li>Volato (NYSEMKT:<a href="https://investorplace.com/stock-quotes/soar-stock-quote/">SOAR</a>) stock is jumping more than 13% on Monday morning.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) shares are up over 13% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Vaxxinity (NASDAQ:<a href="https://investorplace.com/stock-quotes/vaxx-stock-quote/">VAXX</a>) stock is crashing more than 55% on the company&rsquo;s <a href="https://finance.yahoo.com/news/vaxxinity-announces-intention-voluntarily-delist-202700884.html">plans to delist its shares</a>.</li>



<li>EzFill (NASDAQ:<a href="https://investorplace.com/stock-quotes/ezfl-stock-quote/">EZFL</a>) shares are plummeting close to 37% this morning.</li>



<li>Hepion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/hepa-stock-quote/">HEPA</a>) stock is diving over 29% on plans to <a href="https://www.nasdaq.com/press-release/hepion-pharmaceuticals-initiates-wind-down-activities-in-phase-2b-ascend-nash-trial">wind down a clinical trial</a>.</li>



<li>iLearningEngines (NASDAQ:<a href="https://investorplace.com/stock-quotes/aile-stock-quote/">AILE</a>) shares are tumbling more than 21% after <a href="https://finance.yahoo.com/news/ilearningengines-inc-becomes-publicly-traded-200500132.html">going public last week</a>.</li>



<li>Redwoods Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/rwod-stock-quote/">RWOD</a>) stock is taking an over 15% beating <a href="https://investorplace.com/2024/04/why-is-redwoods-acquisition-rwod-stock-up-72-today/">after a recent rally</a>.</li>



<li>Biophytis (NASDAQ:<a href="https://investorplace.com/stock-quotes/bpts-stock-quote/">BPTS</a>) shares are sliding more than 15% ahead of <a href="https://www.nasdaq.com/press-release/biophytis-announces-ratio-change-under-its-american-depositary-receipt-adr-program-0">a ratio change tomorrow</a>.</li>



<li>Adlai Nortye (NASDAQ:<a href="https://investorplace.com/stock-quotes/anl-stock-quote/">ANL</a>) stock is dropping nearly 15% today.</li>



<li>BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) shares are falling over 13% this morning.</li>



<li>Sunshine Biopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/sbfm-stock-quote/">SBFM</a>) stock is decreasing more than 12% today.</li>



<li>Indonesia Energy (NYSEMKT:<a href="https://investorplace.com/stock-quotes/indo-stock-quote/">INDO</a>) shares close out our pre-market stock movers down over 10%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-april-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Adlai Nortye Ltd. Sponsored ADR (ANL) has released an update. Adlai Nortye Ltd., a biotech firm, will present preliminary data at ASCO 2024 on its ...

Adlai Nortye to Unveil Cancer Drug Data at ASCO 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning!



Moving stocks this morning are new agreements and deals, clinical trial data, a bankruptcy filing and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is rocketing more than 205% after announcing a <a href="https://www.nasdaq.com/press-release/microalgo-inc-nasdaq-mlgo-announced-jointly-establish-micro-consciousness-quantum">joint micro-consciousness quantum research center</a> with WIMI (NASDAQ:<a href="https://investorplace.com/stock-quotes/wimi-stock-quote/">WIMI</a>).</li>



<li>Fresh2 Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/fres-stock-quote/">FRES</a>) shares are soaring over 74% alongside heavy pre-market trading.</li>



<li>Core Scientific (NASDAQ:<a href="https://investorplace.com/stock-quotes/corz-stock-quote/">CORZ</a>) stock is surging more than 48% on an <a href="https://www.businesswire.com/news/home/20240603752657/en/Core-Scientific-to-Provide-Approximately-200-MW-of-Infrastructure-to-Host-CoreWeave%E2%80%99s-High-Performance-Computing-Services-Capturing-Significant-AI-Compute-Opportunity">artificial intelligence (AI) infrastructure deal</a>.</li>



<li>Annexon (NASDAQ:<a href="https://investorplace.com/stock-quotes/annx-stock-quote/">ANNX</a>) shares are increasing over 33% on positive <a href="https://www.nasdaq.com/press-release/annexon-announces-positive-topline-results-pivotal-phase-3-trial-first-class-c1q">Phase 3 clinical trial results</a>.</li>



<li>Plutonian Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/pltn-stock-quote/">PLTN</a>) stock is rising close to 30% without any clear news this morning.</li>



<li>Datasea (NASDAQ:<a href="https://investorplace.com/stock-quotes/dtss-stock-quote/">DTSS</a>) shares are gaining more than 21% on Tuesday morning.</li>



<li>SunLink Health Systems (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ssy-stock-quote/">SSY</a>) stock is climbing over 21% after <a href="https://www.nasdaq.com/press-release/sunlink-health-systems-inc-announces-sale-trace-extended-care-rehab-2024-06-03">selling some of its assets</a>.</li>



<li>Lexaria Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/lexx-stock-quote/">LEXX</a>) shares are heading 18% higher on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318368667&amp;type=PDF&amp;symbol=LEXX&amp;cdn=3c5f428b59a4d15cb4a8011d5c00dc9b&amp;companyName=Lexaria+Bioscience+Corp.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-06-03">secondary stock offering</a>.</li>



<li>FibroGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) stock is jumping more than 16% on a <a href="https://finance.yahoo.com/news/fibrogen-announces-clinical-trial-supply-200500592.html">new clinical trial agreement</a>.</li>



<li>Adlai Nortye (NASDAQ:<a href="https://investorplace.com/stock-quotes/anl-stock-quote/">ANL</a>) shares are up nearly 16% on Tuesday.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Lufax (NYSE:<a href="https://investorplace.com/stock-quotes/lu-stock-quote/">LU</a>) stock is plummeting more than 51% without any apparent news from the company.</li>



<li>Hywin (NASDAQ:<a href="https://investorplace.com/stock-quotes/hyw-stock-quote/">HYW</a>) shares are diving over 24% after a massive rally on Monday.</li>



<li>Avalon Globocare (NASDAQ:<a href="https://investorplace.com/stock-quotes/albt-stock-quote/">ALBT</a>) stock is tumbling more than 20% after a major rally yesterday.</li>



<li>Binah Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/bcg-stock-quote/">BCG</a>) shares are taking an over 17% beating without any news to report today.</li>



<li>CalAmp (NASDAQ:<a href="https://investorplace.com/stock-quotes/camp-stock-quote/">CAMP</a>) stock is sliding more than 15% following <a href="https://finance.yahoo.com/news/calamp-reaches-comprehensive-agreement-significantly-132500316.html">a bankruptcy filing</a>.</li>



<li>Sequans Communications (NYSE:<a href="https://investorplace.com/stock-quotes/sqns-stock-quote/">SQNS</a>) shares are dropping over 14% on Tuesday morning.</li>



<li>Direxion Daily MSCI India Bull 2X Shares (NYSEARCA:<a href="https://investorplace.com/stock-quotes/indl-stock-quote/">INDL</a>) are falling more than 14% this morning.</li>



<li>MingZhu Logistics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ygmz-stock-quote/">YGMZ</a>) stock is slipping over 14% after a rally yesterday.</li>



<li>Primech (NASDAQ:<a href="https://investorplace.com/stock-quotes/pmec-stock-quote/">PMEC</a>) shares are dipping 14% after jumping yesterday.</li>



<li>A2Z Smart Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/az-stock-quote/">AZ</a>) stock closes out our pre-market stock movers down over 12%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-june-4th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Adlai Nortye Ltd. Sponsored ADR (ANL) has released an update. Adlai Nortye Ltd. announced a significant leadership change with Dr. Lars E. Birgerso...

Adlai Nortye Announces Executive Leadership Transition

Adlai Nortye Ltd. Sponsored ADR (ANL) has released an update. Adlai Nortye Ltd. has reported its first-half financial results for 2024, including a...

Adlai Nortye Reports Strong 2024 Mid-Year Results

Adlai Nortye reports 1H results

Adlai Nortye Ltd. Sponsored ADR (ANL) has received a new Buy rating, initiated by H.C. Wainwright analyst, Joseph Pantginis. Joseph Pantginis has g...

Buy Rating Affirmed for Adlai Nortye Amid Strong Pipeline and Strategic Immuno-Oncology Focus

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Adlai Nortye Ltd. Sponsored ADR (ANL – Research Report). The associ...

Adlai Nortye Ltd.'s Promising Oncology Pipeline: Key Updates on AN4005 and AN2025 Drive Buy Rating

Warning: ANL is at high risk of performing badly

AILE

ALBT

ANNX

BPTS

BSGM

CAMP

CORZ

CSLR

DRMA

DTSS

EZFL

FGEN

FRES

GRTX

HEPA

HGAS

INDL

INDO

LEXX

MLEC

MLGO

PALI

PLTN

PMEC

PRTG

RWOD

SBFM

SOAR

SPCB

SQNS

VAXX

WIMI

YGMZ

Health Care

Press Releases

Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy

Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024

Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors

Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress

Comments

Adlai Nortye

Notizie

Ultime notizie per Adlai Nortye (NASDAQ:ANL) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO